Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
AstraZeneca
Moodys
McKesson
Express Scripts

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Fasiglifam

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Fasiglifam?

Fasiglifam is an investigational drug.

There have been 10 clinical trials for Fasiglifam. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2012.

The most common disease conditions in clinical trials are Diabetes Mellitus, Diabetes Mellitus, Type 2, and Kidney Diseases. The leading clinical trial sponsors are Takeda and [disabled in preview].

There are thirty-two US patents protecting this investigational drug and three hundred and two international patents.

Recent Clinical Trials for Fasiglifam
TitleSponsorPhase
Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on HemodialysisTakedaPhase 3
Fasiglifam 25 mg BID vs 50 mg QDTakedaPhase 2
Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 DiabetesTakedaPhase 3

See all Fasiglifam clinical trials

Clinical Trial Summary for Fasiglifam

Top disease conditions for Fasiglifam
Top clinical trial sponsors for Fasiglifam

See all Fasiglifam clinical trials

US Patents for Fasiglifam

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Fasiglifam   Start Trial Combination therapy Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
Fasiglifam   Start Trial Heterocyclic compounds CADILA HEALTHCARE LIMITED (Ahmedabad, Gujarat, IN)   Start Trial
Fasiglifam   Start Trial Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Dow
Medtronic
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.